Source:http://linkedlifedata.com/resource/pubmed/id/12353620
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2002-9-30
|
pubmed:abstractText |
The bioavailability of a series of novel acylated ascorbic acid derivatives, 6-O-acyl-2-O-alpha-D-glucopyranosyl-L-ascorbic acids (6-Acyl-AA-2G), as an ascorbic acid (AA) supplement was investigated in rats and guinea pigs. Oral administration of 6-Acyl-AA-2G to rats resulted in an increase in the plasma AA level. However, the intact form was not detectable in the plasma by high-performance liquid chromatography, indicating its hydrolysis through the process of absorption. After an intravenous injection to rats of 6-Octa-AA-2G as a representative derivative, the intact form rapidly disappeared from the plasma, being followed by a prolonged and marked elevation of the plasma AA level. Various tissue homogenates from guinea pigs were examined for their releasing activity of AA, 2-O-alpha-D-glucopyranosyl-L-ascorbic acid (AA-2G) and 6-O-acyl-AA from 6-Acyl-AA-2G. High activity was observed in the small intestine. These hydrolytic activities to AA and 6-O-acyl-AA were completely inhibited by castanospermine, an alpha-glucosidase inhibitor, and AA-2G was observed as the only resulting hydrolysate, suggesting the participation of alpha-glucosidase and esterase in the in vivo hydrolysis of 6-Acyl-AA-2G. 6-Octa-AA-2G was found to exhibit an obvious therapeutic effect in scorbutic guinea pigs from its repeated oral administration. These results indicate that 6-Acyl-AA-2G is a readily available source of AA activity in vivo, and may be useful as an effective pharmacological agent and as a promising food additive.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0916-8451
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
66
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1628-34
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12353620-Animals,
pubmed-meshheading:12353620-Ascorbic Acid,
pubmed-meshheading:12353620-Ascorbic Acid Deficiency,
pubmed-meshheading:12353620-Biological Availability,
pubmed-meshheading:12353620-Brain,
pubmed-meshheading:12353620-Dietary Supplements,
pubmed-meshheading:12353620-Esterases,
pubmed-meshheading:12353620-Guinea Pigs,
pubmed-meshheading:12353620-Hydrolysis,
pubmed-meshheading:12353620-Intestine, Small,
pubmed-meshheading:12353620-Liver,
pubmed-meshheading:12353620-Male,
pubmed-meshheading:12353620-Rats,
pubmed-meshheading:12353620-Rats, Wistar,
pubmed-meshheading:12353620-Scurvy,
pubmed-meshheading:12353620-Skin,
pubmed-meshheading:12353620-alpha-Glucosidases
|
pubmed:year |
2002
|
pubmed:articleTitle |
Bioavailability of a series of novel acylated ascorbic acid derivatives, 6-O-acyl-2-O-alpha-D-glucopyranosyl-L-ascorbic acids, as an ascorbic acid supplement in rats and guinea pigs.
|
pubmed:affiliation |
Department of Immunochemistry, Faculty of Pharmaceutical Sciences, Okayama University, Japan.
|
pubmed:publicationType |
Journal Article
|